Aziz Moqrich has been awarded the SATT IMPACT 2022 Prize for his team’s work on the TAFA4 Protein


Aziz Moqrich has been awarded the SATT IMPACT 2022 prize for his team’s work on the TAFA4 protein.

Dr Moqrich is a Research Director at the IBDM laboratory (part of CNRS, the French Centre National de la Recherche Scientifique) and co-founder of Tafalgie Therapeutics. The award recognizes his major discoveries, which have contributed to substantial advances in biology, and more specifically in pain research and associated innovative treatments.

SATT Sud-Est is the reference TTO (Technology Transfer Office) for Aix-Marseille University and CNRS unit The SATT was instrumental in the valorisation process of the work that led to the discovery of the TAFA4 protein’s therapeutic potential as a painkiller. This was achieved through several funding mechanisms as well as a series of administrative interventions with CNRS and AMU that facilitated the launch of Tafalgie Therapeutics. Notably, SATT Sud-Est managed the TAFA4 patent and its first license agreement with Tafalgie Therapeutics, in which SATT Sud-Est is one of the first investors.

During the awards ceremony, Aziz Moqrich presented his discovery of a new generation of non-opioid painkillers and Tafalgie Therapeutics’ work in this field.

Congratulations on this well-deserved honour! 

Visit our contact page